药物对比
Canagliflozin vs Miglitol
比较Canagliflozin与Miglitol治疗2型糖尿病。SGLT2抑制剂与α-葡萄糖苷酶抑制剂在机制、心血管获益、胃肠道影响及患者适用性方面存在差异。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when adding a second oral agent after metformin in type 2 diabetes, weighing SGLT2 cardiorenal benefits against alpha-glucosidase postprandial control.
结论
Neither drug is universally superior; Canagliflozin provides extra cardiovascular and renal protection while Miglitol offers targeted mealtime glucose lowering with a distinct side-effect profile.
全部药物对比